Payment overview · 2025
General Payments
$472.84
13 reported records · 7 companies
Healthcare provider profile · identity verified
Alan L Tannenbaum, MD
Allopathic & Osteopathic Physicians|Internal Medicine · CAPE CORAL, FL · NPI 1235117342
Verified facts
What the public records show
CMS Open Payments records show Alan L Tannenbaum, MD received $472.84 in general payments during 2025 across 13 reported records.
AstraZeneca Pharmaceuticals LP accounted for 26.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abrysvo, Eliquis, Jardiance, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 162 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 98 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $124.97 | 26.4% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $99.06 | 20.9% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $65.02 | 13.8% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $60.03 | 12.7% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $53.73 | 11.4% | 3 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $53.36 | 11.3% | 2 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$16.67 | 3.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $472.84 | 13 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $124.97 | 1 | 2025 |
Source payment records
|
|||||
| Intracept Normalized: intracept |
Device | Boston Scientific Corporation | $99.06 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $60.03 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $53.73 | 3 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $53.36 | 2 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $53.36 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $46.75 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $46.75 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $46.75 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $18.27 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $18.27 | 1 | 2025 |
Source payment records
|
|||||
| VENASEAL Normalized: venaseal |
Device | Medtronic, Inc. | $16.67 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABRYSVO abrysvo |
2025 | Abrysvo | 2024 | 17 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 98 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 162 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 62 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
78 | 23 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
77 | 77 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
52 | 38 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
62 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
162 | 47 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
17 | 17 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
98 | 36 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 493 | 163 |
| Amlodipine Besylate | Amlodipine Besylate | 412 | 135 |
| Levothyroxine Sodium | Levothyroxine Sodium | 299 | 89 |
| Lisinopril | Lisinopril | 287 | 86 |
| Metoprolol Succinate | Metoprolol Succinate | 287 | 98 |
| Meloxicam | Meloxicam | 261 | 93 |
| Metformin Hcl | Metformin Hcl | 250 | 77 |
| Omeprazole | Omeprazole | 244 | 76 |
| Alprazolam | Alprazolam | 241 | 42 |
| Simvastatin | Simvastatin | 235 | 71 |
| Zolpidem Tartrate | Zolpidem Tartrate | 235 | 38 |
| Allopurinol | Allopurinol | 199 | 64 |
| Tamsulosin Hcl | Tamsulosin Hcl | 190 | 68 |
| Jardiance | Empagliflozin | 162 | 47 |
| Gabapentin | Gabapentin | 158 | 53 |
| Pantoprazole Sodium | Pantoprazole Sodium | 157 | 59 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 148 | 61 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 141 | 42 |
| Hydrochlorothiazide | Hydrochlorothiazide | 140 | 48 |
| Losartan Potassium | Losartan Potassium | 133 | 46 |
| Trazodone Hcl | Trazodone Hcl | 130 | 42 |
| Cefuroxime | Cefuroxime Axetil | 124 | 93 |
| Carvedilol | Carvedilol | 108 | 38 |
| Eliquis | Apixaban | 98 | 36 |
| Tramadol Hcl | Tramadol Hcl | 98 | 17 |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 96 | 24 |
| Furosemide | Furosemide | 95 | 35 |
| Montelukast Sodium | Montelukast Sodium | 85 | 33 |
| Farxiga | Dapagliflozin Propanediol | 78 | 23 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 77 | 29 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 77 | 77 |
| Ramipril | Ramipril | 76 | 24 |
| Clopidogrel | Clopidogrel Bisulfate | 73 | 28 |
| Finasteride | Finasteride | 70 | 22 |
| Metoprolol Tartrate | Metoprolol Tartrate | 70 | 30 |
| Pravastatin Sodium | Pravastatin Sodium | 64 | 22 |
| Potassium Chloride | Potassium Chloride | 62 | 24 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 62 | 19 |
| Fluticasone Propionate | Fluticasone Propionate | 61 | 17 |
| Fenofibrate | Fenofibrate,micronized | 58 | 21 |
| Glipizide | Glipizide | 57 | 23 |
| Citalopram Hbr | Citalopram Hydrobromide | 55 | 16 |
| Ezetimibe | Ezetimibe | 54 | 19 |
| Sertraline Hcl | Sertraline Hcl | 53 | 21 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 52 | 38 |
| Clonazepam | Clonazepam | 51 | suppressed |
| Lorazepam | Lorazepam | 50 | 13 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 47 | 38 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 47 | 27 |
| Atenolol | Atenolol | 46 | 16 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 45 | 18 |
| Spironolactone | Spironolactone | 45 | 16 |
| Entresto | Sacubitril/Valsartan | 44 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 41 | 15 |
| Donepezil Hcl | Donepezil Hcl | 40 | 15 |
| Amitriptyline Hcl | Amitriptyline Hcl | 39 | 11 |
| Fenofibrate | Fenofibrate | 39 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 39 | 13 |
| Pioglitazone Hcl | Pioglitazone Hcl | 39 | 15 |
| Quetiapine Fumarate | Quetiapine Fumarate | 39 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 38 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 37 | suppressed |
| Temazepam | Temazepam | 37 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 36 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 35 | 12 |
| Xarelto | Rivaroxaban | 35 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 34 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 34 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 33 | 16 |
| Eszopiclone | Eszopiclone | 32 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 32 | 12 |
| Warfarin Sodium | Warfarin Sodium | 31 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 30 | 14 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 30 | suppressed |
| Rybelsus | Semaglutide | 30 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 29 | 11 |
| Linzess | Linaclotide | 28 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 27 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 27 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Glipizide Er | Glipizide | 25 | suppressed |
| Mirtazapine | Mirtazapine | 25 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 24 | suppressed |
| Lovastatin | Lovastatin | 24 | suppressed |
| Nifedipine Er | Nifedipine | 23 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 22 | suppressed |
| Torsemide | Torsemide | 22 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 21 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 21 | suppressed |
| Celecoxib | Celecoxib | 21 | suppressed |
| Digoxin | Digoxin | 21 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 21 | suppressed |
| Ssd | Silver Sulfadiazine | 19 | 15 |
| Terazosin Hcl | Terazosin Hcl | 19 | suppressed |
| Bupropion Xl | Bupropion Hcl | 18 | suppressed |
| Trulicity | Dulaglutide | 18 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 18 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 17 | 17 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 17 | suppressed |
| Methylprednisolone | Methylprednisolone | 17 | 14 |
| Mounjaro | Tirzepatide | 17 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 16 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 16 | suppressed |
| Diazepam | Diazepam | 16 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 16 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 16 | suppressed |
| Prednisone | Prednisone | 16 | 11 |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 16 | suppressed |
| Sotalol | Sotalol Hcl | 16 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 15 | suppressed |
| Dutasteride | Dutasteride | 15 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 15 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 14 | 13 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 14 | suppressed |
| Estradiol | Estradiol | 14 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Jantoven | Warfarin Sodium | 14 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 14 | suppressed |
| Tradjenta | Linagliptin | 14 | suppressed |
| Valsartan | Valsartan | 14 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 14 | suppressed |
| Levofloxacin | Levofloxacin | 13 | suppressed |
| Naproxen | Naproxen | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 12 | suppressed |
| Lactulose | Lactulose | 12 | suppressed |
| Ozempic | Semaglutide | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 11 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 11 | suppressed |
| Glimepiride | Glimepiride | 11 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 11 | suppressed |
| Risperidone | Risperidone | 11 | suppressed |
| Synthroid | Levothyroxine Sodium | 11 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $472.84 · 13 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, BREZTRI, CAPVAXIVE, COMIRNATY, ELIQUIS, GARDASIL 9, Intracept, JARDIANCE, NURTEC ODT, PREVNAR 20, TRELEGY ELLIPTA, VENASEAL | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abrysvo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error